Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.1125 -0.116666666666667 -0.129166666666667 -0.1975
Stock impact report

ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)

ACHAOGEN (AKAO) 
Last achaogen earnings: 3/28 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.achaogen.com/investor-overview
Company Research Source: GlobeNewswire
? ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae ? Working in the Lab Blake Wise, Chief Executive Officer at Achaogen High-Resolution Achaogen company logo ? ZEMDRI is the only once-daily aminoglycoside therapy approved for use in cUTI ? ? ZEMDRI has microbiological activity against pathogens designated by the CDC as urgent and serious public health threats, including carba Show less Read more
Impact Snapshot
Event Time:
AKAO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for AKAO alerts
Opt-in for
AKAO alerts

from News Quantified
Opt-in for
AKAO alerts

from News Quantified